For the more than half a million Americans on hemodialysis, the lifeline is a surgically created arteriovenous fistula, or AVF, in the arm. The procedure connects an artery to a vein, creating a robust vessel that can withstand the repeated needle sticks required for treatment. But this access point is fragile. It can narrow or clot, often without warning, leading to a sudden, painful failure that sends patients to the emergency room and can require urgent surgery to restore. The current standard of care, a physical exam and periodic ultrasound at a clinic, is notoriously poor at catching these problems early. A new company, spun from a university lab in Champaign, Illinois, is betting that the answer lies in listening to the fistula from the patient's home, every single day.
Auvi Labs is building a wearable ultrasound patch, called Beacon, designed to detect the early acoustic signatures of AVF narrowing. The concept is disarmingly simple in its patient-facing routine. A person on dialysis would wear the small patch on their arm for about ten minutes a day [YouTube]. During that time, the device collects auditory information from the blood flow through the fistula, looking for the subtle changes in sound that signal trouble [Illinois Medicine, 2024]. The goal is to give clinicians a continuous data stream, moving monitoring from a sporadic clinic event to a daily ritual, and flagging issues long before they become catastrophic.
The Clinical Wedge in a $50 Billion Problem
The bet is not on a novel treatment, but on a critical piece of preventative infrastructure. Hemodialysis is a massive, costly segment of the U.S. healthcare system, with Medicare spending exceeding $50 billion annually on end-stage renal disease. A significant portion of that cost is driven by complications related to vascular access. Failed fistulas lead to hospitalizations, invasive procedures, and the temporary use of riskier central venous catheters. For nephrologists and dialysis nurses, access management is a constant, high-stakes puzzle. Auvi's proposed tool aims to sit at the intersection of a clear clinical need and a reimbursement pathway built around avoiding expensive adverse events. Success would mean proving that earlier intervention, guided by their data, improves patient outcomes and reduces total cost of care,a compelling value proposition for large dialysis organizations and payers.
From Lab Bench to Patient's Arm
The company's origins are firmly academic. Auvi Labs was spun out of the University of Illinois at Urbana-Champaign in 2024, and its initial funding and validation have come through that ecosystem. The team, led by CEO Rishab Veldur and COO Kevin Volkema, secured second place and a $35,000 investment in the 2024 Cozad New Venture Challenge [Illinois Medicine, 2024]. Public records indicate follow-on funding totaling approximately $136,000, with Illinois Ventures listed as an investor [SignalBase][Illinois Ventures]. The technical foundation appears to be the translation of ultrasound sensing into a low-power, wearable form factor, a challenge the team has been working on since its founding.
| Role | Name |
|---|---|
| CEO | Rishab Veldur |
| COO | Kevin Volkema |
| Founder | Satyansh Yeluri |
| Table: Auvi Labs' founding team, as identified in public records [BBB profile][Delta: HealthTech Innovators]. |
The Long Road to a Regulated Device
For all the elegance of its premise, Auvi Labs faces a path defined by hard milestones common to medical hardware startups. The company is at a very early, pre-seed stage. The capital raised to date is modest, primarily from university-affiliated sources, suggesting a forthcoming institutional seed round will be necessary to fund the rigorous development and clinical validation required for FDA clearance. The product is a Class II medical device, which means Auvi must compile substantial clinical evidence to demonstrate safety and effectiveness for its intended use. This process is measured in years and millions of dollars. Furthermore, the company must navigate the practicalities of user-centered design for a chronically ill, often elderly population, ensuring the patch is truly simple and reliable for daily home use.
The competitive landscape, while not crowded with direct replicas, is defined by the inertia of the current standard of care and adjacent monitoring technologies. The risks Auvi must mitigate are multifaceted:
- Clinical evidence. The core assumption,that daily acoustic monitoring predicts failure better than current methods,must be proven in a controlled clinical study.
- Regulatory strategy. A 510(k) clearance pathway will require identifying a appropriate predicate device and building a substantial technical file.
- Commercial adoption. Even with FDA clearance, convincing large, conservative dialysis providers to integrate a new data stream into clinical workflow is a separate sales challenge.
The Patient at the End of the Data Stream
The ambition here is narrowly focused on a specific disease state: end-stage renal disease patients reliant on hemodialysis via an arteriovenous fistula. This population endures a grueling routine of thrice-weekly clinic visits, dietary restrictions, and the constant threat of complications. Today, monitoring that crucial fistula involves a clinician's physical palpation for a "thrill" and a periodic, scheduled ultrasound exam. It's a system that can miss the gradual decline happening between visits. If Auvi Labs succeeds, the standard of care could shift toward a more proactive, patient-empowered model. Instead of waiting for a problem to become severe enough to feel, a nurse coordinator might receive an alert from the Beacon system, review the trend data, and schedule a timely intervention,a planned angioplasty to open a narrowing, perhaps, instead of an emergency thrombectomy to clear a total clot. For the patient, that difference is not merely clinical; it's the difference between stability and crisis, between planned care and the emergency room.
Sources
- [Auvi Labs] Auvi Labs Home Page | https://www.auvilabs.com/
- [BBB] BBB Business Profile | https://www.bbb.org/us/il/chicago/profile/dialysis-clinic/auvi-labs-0654-1000139723
- [Delta: HealthTech Innovators] Podcast Appearance | https://podcasts.apple.com/ca/podcast/delta-healthtech-innovators/id1703827145
- [Illinois Medicine, 2024] Solution to Improve Dialysis Patient Care Earns CI MED Start-up Winning Investment | https://medicine.illinois.edu/news/solution-to-improve-dialysis-patient-care-earns-ci-med-start-up-winning-investment
- [Illinois Ventures] Portfolio Page | https://illinoisventures.com/portfolio/
- [SignalBase] Auvi Labs Raises $101K Seed Funding | https://www.trysignalbase.com/news/funding/auvi-labs-raises-101k-seed-funding-to-advance-dialysis-access-monitoring
- [YouTube] How Auvi Labs is Building a Wearable Ultrasound Device | https://www.youtube.com/watch?v=fDuFXmx-7DY